Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The prediction of rapid progression in patients with diabetic kidney disease (DKD) remains a global challenge. This study aimed to evaluate the prognostic utility of two non-invasive biomarkers—neutrophil gelatinase-associated lipocalin (NGAL) and monocyte chemoattractant protein-1 (MCP-1)—for identifying rapid DKD progression.
This prospective observational study included 145 patients with type 2 diabetes mellitus (T2DM) with DKD enrolled between October 2021 and June 2024. Patients were categorized as rapid or non-rapid progressors based on an estimated glomerular filtration rate (eGFR) decline of >5 ml/min/1.73 m²/year. Baseline urinary NGAL (uNGAL) and MCP-1 (uMCP-1) levels were measured using ELISA. Clinical parameters, risk factors, and biomarker associations with disease progression were analyzed using univariate and multivariate analyses.The research conducted in this study adhered to the principles outlined in the Declaration of Helsinki and was approved by the Kasturba Medical College and Kasturba Hospital Institutional Ethics Committee. Written informed consent was obtained from all the participants before study enrollment.
During a median follow-up of 1.3 years, 38.6% of patients were rapid progressors, while 61.3% were non-progressors. Hypertension, cardiovascular disease, elevated systolic blood pressure, higher fasting blood sugar, and increased urine albumin-to-creatinine ratio (uACR) were significantly associated with rapid progression (p < 0.05). Median uNGAL and uMCP-1 levels were significantly higher in rapid progressors (57.6 vs 28.2 ng/ml and 469 vs 220 pg/ml, respectively; p = 0.01), and both increased with albuminuria severity (p = 0.03 and p = 0.01). On multivariate analysis, uNGAL, uMCP-1, and uACR were independent predictors of rapid progression. uMCP-1 demonstrated the highest diagnostic accuracy (AUC = 0.94, sensitivity 94.1%, specificity 89.2% at 381.2 pg/ml), followed by uNGAL (AUC = 0.86, sensitivity 83.4%, specificity 77.3% at 39.8 ng/ml).The cutoff value of the uACR was 969 mg/g, with an AUC of 0.78 (95% CI: 0.699–0.872), 66% sensitivity and 98% specificity. A combined biomarker panel of uMCP-1, uNGAL, and uACR further improved predictability (AUC = 0.96).
A significant proportion of DKD patients exhibited rapid disease progression. Patients with elevated urinary MCP-1 and NGAL levels had a significantly higher risk of rapid DKD progression. uMCP-1 demonstrated superior diagnostic performance compared to uNGAL and uACR. The combined biomarker panel enhanced predictive accuracy, supporting a multipanel biomarker approach for early identification of high-risk patients and improved risk stratification in DKD.
